Advances in the approach to novel drug clinical development for breast cancer (Q38206546)

31 August 2017

Advances in the approach to novel drug clinical development for breast cancer (English)

1 reference

31 August 2017

Cristiano Ferrario

1

1 reference

PubMed ID

24758225

31 August 2017

Gerald Batist

series ordinal

2

1 reference

PubMed ID

24758225

31 August 2017

language of work or name

English

0 references

publication date

23 April 2014

1 reference

Expert Opinion on Drug Discovery

31 August 2017

1 reference

31 August 2017

9

1 reference

31 August 2017

647-668

1 reference

31 August 2017

6

1 reference

Time for more optimism in metastatic breast cancer?

31 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Breast cancer: achievements in adjuvant systemic therapies in the pre-genomic era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Definitive results of a phase III adjuvant trial comparing three chemotherapy regimens in women with operable, node-positive breast cancer: the NSABP B-38 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Detecting somatic point mutations in cancer genome sequencing data: a comparison of mutation callers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Gene expression profiling predicts clinical outcome of breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Metastatic breast cancer: are we treating the same patients as in the past?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Aromatase inhibitors: from bench to bedside and back

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Continuous cultures of fused cells secreting antibody of predefined specificity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Humanized antibodies for therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Adjuvant trastuzumab in HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Phase III randomized study comparing docetaxel plus trastuzumab with vinorelbine plus trastuzumab as first-line therapy of metastatic or locally advanced human epidermal growth factor receptor 2-positive breast cancer: the HERNATA study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Bevacizumab in metastatic breast cancer: a meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Biomarker results from the AVADO phase 3 trial of first-line bevacizumab plus docetaxel for HER2-negative metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Aromatase inhibition 2013: clinical state of the art and questions that remain to be solved

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Role of tyrosine kinase inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Phase III trial of sunitinib in combination with capecitabine versus capecitabine monotherapy for the treatment of patients with pretreated metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Molecular predictors of response to trastuzumab and lapatinib in breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

A systematic review of trastuzumab and lapatinib in the treatment of women with brain metastases from HER2-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Triple negative tumours: a critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Comparison of basal-like triple-negative breast cancer defined by morphology, immunohistochemistry and transcriptional profiles

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Triple-negative breast cancer: BRCAness and concordance of clinical features with BRCA1-mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

The role of BRCA1 in the cellular response to chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Responsiveness of intrinsic subtypes to adjuvant anthracycline substitution in the NCIC.CTG MA.5 randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Cyclophosphamide dose intensification may circumvent anthracycline resistance of p53 mutant breast cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Inducing synthetic lethality using PARP inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Effects of novel inhibitors of poly(ADP-ribose) polymerase-1 and the DNA-dependent protein kinase on enzyme activities and DNA repair.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind, randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Fulvestrant (Faslodex) -- how to make a good drug better

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, mult

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized 'FIRST' study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Iniparib plus chemotherapy in metastatic triple-negative breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Failure of iniparib to inhibit poly(ADP-Ribose) polymerase in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Appraising iniparib, the PARP inhibitor that never was--what must we learn?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers--role of estrogen receptor and HER2 reactivation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Combination anastrozole and fulvestrant in metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Model systems: mechanisms involved in the loss of sensitivity to letrozole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parall

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer: TBCRC 006

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Redundant cyclin overexpression and gene amplification in breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Proliferation of cancer cells despite CDK2 inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Multiple roles of cyclin-dependent kinase 4/6 inhibitors in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Independent review of E2100: a phase III trial of bevacizumab plus paclitaxel versus paclitaxel in women with metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Molecular mechanisms of resistance to tumour anti-angiogenic strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Mechanisms of resistance to vascular endothelial growth factor blockade

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Resistance to cancer treatment: the role of somatic genetic events and the challenges for targeted therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Biopsies: next-generation biospecimens for tailoring therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Sirolimus and temsirolimus for epithelioid angiomyolipoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Hormonal receptor, human epidermal growth factor receptor-2, and Ki67 discordance between primary breast cancer and paired metastases: clinical impact

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Inhibition of mTOR activity restores tamoxifen response in breast cancer cells with aberrant Akt Activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Comprehensive molecular portraits of human breast tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Randomized phase III placebo-controlled trial of letrozole plus oral temsirolimus as first-line endocrine therapy in postmenopausal women with locally advanced or metastatic breast cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

mTOR inhibitors in breast cancer: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Tumor genetic testing for patient selection in phase I clinical trials: the case of PI3K inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

D538G mutation in estrogen receptor-α: A novel mechanism for acquired endocrine resistance in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Activating ESR1 mutations in hormone-resistant metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Evolving strategies for overcoming resistance to HER2-directed therapy: targeting the PI3K/Akt/mTOR pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Protein kinase A activation confers resistance to trastuzumab in human breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Both t-Darpp and DARPP-32 can cause resistance to trastuzumab in breast cancer cells and are frequently expressed in primary breast cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Trastuzumab combined with pegylated liposomal doxorubicin in patients with metastatic breast cancer. phase II Study of the Hellenic Cooperative Oncology Group (HeCOG) with biomarker evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Association between gain-of-function mutations in PIK3CA and resistance to HER2-targeted agents in HER2-amplified breast cancer cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Secondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2/M checkpoint activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Stabilization of mutant BRCA1 protein confers PARP inhibitor and platinum resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Metastatic breast cancer: the role of pegylated liposomal doxorubicin after conventional anthracyclines

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Myocet (liposome-encapsulated doxorubicin citrate): a new approach in breast cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Enhancing intracellular taxane delivery: current role and perspectives of nanoparticle albumin-bound paclitaxel in the treatment of advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Trastuzumab emtansine: a unique antibody-drug conjugate in development for human epidermal growth factor receptor 2-positive cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Trastuzumab emtansine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Safety, pharmacokinetics, and activity of GRN1005, a novel conjugate of angiopep-2, a peptide facilitating brain penetration, and paclitaxel, in patients with advanced solid tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Information-theory based surrogate marker evaluation from several randomized clinical trials with continuous true and binary surrogate endpoints

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Neoadjuvant use of hormonal therapy in elderly patients with early or locally advanced hormone receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Neoadjuvant letrozole in postmenopausal estrogen and/or progesterone receptor positive breast cancer: a phase IIb/III trial to investigate optimal duration of preoperative endocrine therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Use of the neo-adjuvant exemestane in post-menopausal estrogen receptor-positive breast cancer: a randomized phase II trial (PTEX46) to investigate the optimal duration of preoperative endocrine therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Use of neoadjuvant data to design adjuvant endocrine therapy trials for breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-bas

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Developing safety criteria for introducing new agents into neoadjuvant trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Drug-diagnostics co-development in oncology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Randomized phase III clinical trial designs for targeted agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Clinical trial designs for predictive biomarker validation: theoretical considerations and practical challenges.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Phase III clinical trials that integrate treatment and biomarker evaluation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Pilot study using molecular profiling of patients' tumors to find potential targets and select treatments for their refractory cancers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Reply to M. Gallén et al and R.S. Midgley et al.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Targeted therapy in metastatic colorectal cancer -- an example of personalised medicine in action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Phase I, dose-escalation study of BKM120, an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Genome sequencing identifies a basis for everolimus sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Identification of selective inhibitors of cancer stem cells by high-throughput screening

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Synthetic lethal screen identification of chemosensitizer loci in cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Adjuvant Capecitabine, Docetaxel, Cyclophosphamide, and Epirubicin for Early Breast Cancer: Final Analysis of the Randomized FinXX Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Molecular prescreening to select patient population in early clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

Response to a specific antioestrogen (ICI 182780) in tamoxifen-resistant breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17460441.2014.911282

10.1517/17460441.2014.911282

21 January 2018

Identifiers

DOI

1 reference

31 August 2017

1 reference

PubMed ID

24758225